Short Bowel Syndrome clinical trials at UCSF

• Registry for Participants With Short Bowel Syndrome

  open to all eligible people

  This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

  San Francisco, California and other locations

Last updated: June 7, 2021